ClinicalTrials.gg
CompletedNCT03579823ALVOPADUpdated Jan 18, 2019

Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers

A Phase 1 interventional study of Adalimumab 100 MG/ML [Humira] and AVT02 100MG/ML in Healthy Volunteers, sponsored by Alvotech Swiss AG. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-18.

Sponsored by Alvotech Swiss AG · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Adalimumab is an immunosuppressive drug that belongs to the family of anti-TNF agents. It contains a monoclonal antibody produced by biotechnology. It is designed to bind to tumor necrosis factor (TNF), a substance that is involved in several auto-immune processes. By binding to TNF, adalimumab blocks its activity, reducing the severity of various chronic inflammatory diseases including Rheumatoid Arthritis, Plaque Psoriasis and others.

Often, the high cost of biologic products may preclude access to the treatment to a big portion of the population worldwide. A biosimilar product that provides comparable safety and efficacy at more affordable cost would fulfill a broader medical need.

Humira has been available on the market for several years. Recently, a higher concentration (100 mg/mL) formulation has been introduced in major markets. Alvotech is developing AVT02, that is a proposed biosimilar of adalimumab containing high concentration (100 mg/mL) of active ingredient.

The objective of this clinical trial is to assess the similarity of AVT02 (100 mg/mL) with Humira (100 mg/mL), in terms of tolerability, safety (including immunogenicity) and compare the pharmacokinetics in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Male and female healthy adult subjects willing to sign an Form and able to undergo protocol related procedures.
  • Age: 18 to 55 years, inclusive.
  • (BMI): 19.0 to 30.0 kg per m2.
  • Medical history without major pathology, at the discretion of Principal Investigator.
  • Resting supine systolic blood pressure of ≤150 mmHg and diastolic blood pressure of ≤90 mmHg. Other vital signs showing no deviations according to the Principal Investigator's judgment.
  • Computerised 12-lead recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the Principal Investigator.
  • Subjects who do not smoke tobacco products or use nicotine replacement therapy or e-cigarettes.

Main Exclusion Criteria:

  • Evidence of clinically relevant pathology.
  • Unable to follow protocol instructions in the opinion of the Principal Investigator.
  • History of relevant drug and or food allergies.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study.
  • Known history of previous exposure to adalimumab or other anti-TNF-alpha molecules.
  • Any past or concurrent medical conditions potentially increasing the subject's risks, or would have interfered with the study evaluation, procedures, or study completion. Examples of these include medical history with evidence of clinically relevant pathology (e.g., , demyelinating disorders, herpes zoster, or hepatic, gallbladder or pancreatic diseases).
  • Presence of . Asthma in the childhood is allowed.
  • Evidence of a recent, within 6 months, infection requiring hospitalisation or intravenous antibiotic use.
  • Subject has a positive test for Tuberculosis (TB) during screening or a known history of active or latent TB, except documented and complete adequate treatment of TB.
  • Having received during the 4 weeks before screening or have the intention to receive vaccination during the study.
  • Positive for surface antigen (HBsAg), hepatitis B core antibody (HbcAb), anti- virus antibodies (HCV), or anti- (HIV) 1 on 2 antibodies at screening.
  • Impaired liver function
  • Any persons who are an employee of the Principal Investigator, clinical centre, clinical research organisation or Sponsor, a relative of an employee of the clinical centre, the Investigator, Clinical Research Organization (CRO) or the Sponsor.
  • Other inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    AVT02 100 MG/ML

    Single subcutaneous injection of 40 mg of AVT02 (100MG/ML)

    Drug: AVT02 100MG/ML

  • Active comparator
    Adalimumab 100 MG/ML [HUMIRA]

    Single subcutaneous injection of 40 mg of Adalimumab (100MG/ML) \[HUMIRA\]

    Drug: Adalimumab 100 MG/ML [Humira]

Interventions

  • DrugAdalimumab 100 MG/ML [Humira]

    Drug page: Adalimumab

    prefilled syringe at a concentration of 100MG/ML and delivering 40MG of adalimumab, as a single dose on day 1 day 1

  • DrugAVT02 100MG/ML

    Drug page: Adalimumab

    prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1

06

What researchers measure

Primary outcomes

  1. Change from baseline blood pressure at 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing

    Measurement of blood pressure (systolic and diastolic in mm Hg)

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing

  2. Change from baseline heart rate at 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing

    Measure of heart rate (beats per minute)

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing

  3. Change from baseline body temperature at 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing

    Measurement of oral temperature (Celsius degree)

    Time frame: Predose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 64 days post dosing

  4. Change from baseline electrocardiogram at 1, 2, 5, 9, 64 days post dosing

    Analysis of 12-lead electrocardiogram

    Time frame: Predose and 1, 2, 5, 9, 64 days post dosing

  5. Change from baseline red blood cells at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure red blood cells count, (unit/mm3)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  6. Change from baseline haemoglobin at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure haemoglobin (g/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  7. Change from baseline white blood cells at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure white blood cells count, (unit/mm3)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  8. Change from baseline platelets at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure platelets count, (unit/mm3)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  9. Change from baseline blood gamma glutamyl transferase at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure gamma glutamyl transferase (UI/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  10. Change from baseline blood aspartate aminotransferase at 2, 3, 5, 9, 64 days post

    Blood collection to measure aspartate aminotransferase (UI/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  11. Change from baseline blood alanine aminotransferase at 2, 3, 5, 9, 64 days post

    Blood collection to measure alanine aminotransferase (UI/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  12. Change from baseline blood potassium at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure potassium (mmol/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  13. Change from baseline blood sodium at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure sodium (mmol/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  14. Change from baseline blood calcium at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure calcium (mmol/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  15. Change from baseline blood phosphate at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure phosphate (mmol/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  16. Change from baseline blood chloride at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure chloride (mmol/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  17. Change from baseline blood bicarbonate at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure bicarbonate (mmol/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  18. Change from baseline blood creatinine at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure creatinine (micromol/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  19. Change from baseline blood bilirubin at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure Bilirubin (micromol/L)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  20. Change from baseline international normalised ratio at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure international normalised ratio

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  21. Change from baseline prothrombin time at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure prothrombin time (sec)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  22. Change from baseline partial prothrombin time at 2, 3, 5, 9, 64 days post dosing

    Blood collection to measure partial prothrombin time (sec)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  23. Change from baseline activated partial thromboplastin time at 2, 3, 5, 9, 64 days post

    Blood collection to measure activated partial thromboplastin time (sec)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  24. Change from baseline thrombin time at 2, 3, 5, 9, 64 days post

    Blood collection to measure thrombin time (sec)

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  25. Change from baseline urine leucocytes at 2, 3, 5, 9, 64 days post dosing

    Urine sample collection to measure leucocytes

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  26. Change from baseline urine glucose at 2, 3, 5, 9, 64 days post dosing

    Urine sample collection to measure glucose

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

  27. Change from baseline urine protein at 2, 3, 5, 9, 64 days post dosing

    Urine sample collection to measure protein

    Time frame: Predose and 2, 3, 5, 9, 64 days post dosing

Secondary outcomes

  1. Area under the plasma concentration-time curve (AUC)

    Venous blood samples will be collected for measurement of Area under the plasma concentration-time curve (AUC) of AVT02 and EU Humira

    Time frame: Over 64 days

  2. Maximum serum concentration

    Venous blood samples will be collected for measurement of serum concentration of AVT02 and EU Humira

    Time frame: Over 64 days

  3. Time to maximum serum concentration

    Evaluation of time to maximum plasma concentration (Tmax) of AVT02 and Humira.

    Time frame: Over 64 days

  4. Terminal half-life

    Evaluation of terminal elimination half-life (T1/2) of AVT02 and Humira

    Time frame: Over 64 days

  5. Volume of distribution

    Evaluation of volume of distribution during the elimination phase (Vz) of AVT02 and Humira

    Time frame: Over 64 days

  6. Clearance

    Evaluation of total plasma clearance (CL) of AVT02 and Humira

    Time frame: Over 64 days

  7. Incidence and titer of anti-drug antibodies to adalimumab

    A blood sample will be collected to measure antibodies to AVT02 and Humira

    Time frame: 15, 29 and 64 days after dosing

07

Study locations

1 site
  • Nucleus Network
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Aug 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2018
First posted
Jul 9, 2018
StartActual
May 21, 2018
Primary completionActual
Aug 24, 2018
CompletionActual
Aug 24, 2018
Last update
Jan 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03579823
Lead sponsor
Alvotech Swiss AG
Responsible party
Sponsor
First posted
Jul 9, 2018
Start date
May 21, 2018
Primary completion
Aug 24, 2018
Completion
Aug 24, 2018
Last update
Jan 18, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion